

Luchino Chessa

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6928669/luchino-chessa-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41
papers

921
citations

13
h-index

30
g-index

56
ext. papers

1,133
ext. citations

4.8
avg, IF

3.05
L-index

#	Paper	IF	Citations
41	Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination.. <i>Vaccines</i> , 2022 , 10,	5.3	1
40	A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population.. <i>Frontiers in Immunology</i> , 2022 , 13, 891147	8.4	0
39	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.. <i>Hepatology</i> , 2021 ,	11.2	3
38	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. <i>Clinical and Experimental Medicine</i> , 2021 , 1	4.9	8
37	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021 , 3, 100248	10.3	10
36	The COVID-19 incidence in Italian regions correlates with low temperature, mobility and PM10 pollution but lethality only with low temperature. <i>Journal of Public Health Research</i> , 2021 , 10,	2.2	2
35	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021 , 75, 1355-1366	13.4	2
34	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
33	Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 41-50	4.2	15
32	Review article: safety of new biologic agents for inflammatory bowel disease in the liver. <i>European Journal of Gastroenterology and Hepatology</i> , 2021 , 33, 623-630	2.2	2
31	Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021 , 16, e0255608	3.7	7
30	Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. <i>Frontiers in Immunology</i> , 2020 , 11, 605688	8.4	39
29	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020 , 14, 362-372	8.8	5
28	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1274-1282	2.4	5
27	HepaDisk - A new quality of life questionnaire for HCV patients. <i>Digestive and Liver Disease</i> , 2019 , 51, 1008-1015	3.3	2
26	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. <i>PLoS ONE</i> , 2019 , 14, e0226615	3.7	4
25	Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study. <i>General Hospital Psychiatry</i> , 2019 , 56, 50-51	5.6	2

24	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018 , 38, 2190-2198	7.9	23
23	Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassaemic Patients with Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2018 , 18,	1.8	2
22	Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?. <i>HIV Clinical Trials</i> , 2018 , 19, 188-196		2
21	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018 , 104, 476-479	1.7	12
20	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
19	Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. <i>Journal of Immigrant and Minority Health</i> , 2017 , 19, 876-882	2.2	1
18	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. <i>BMC Infectious Diseases</i> , 2017 , 17, 734	4	2
17	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2017 ,	13.4	9
16	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017 , 66, 1814-1825	11.2	18
15	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
14	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017 , 12, e0185728	3.7	28
13	The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. <i>Journal of Ultrasound</i> , 2016 , 19, 91-8	3.4	3
12	Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis. <i>PLoS ONE</i> , 2016 , 11, e0146086	3.7	18
11	Can antiretroviral therapy modify the clinical course of HDV infection in HIV-positive patients?. <i>Antiviral Therapy</i> , 2015 , 20, 671-9	1.6	
10	Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma. <i>Human Immunology</i> , 2013 , 74, 1288-94	2.3	6
9	Randomised study comparing 48 and 96 weeks peginterferon E2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013 , 62, 290-8	19.2	88
8	Association of chronic hepatitis C with recurrent brief depression. <i>Journal of Affective Disorders</i> , 2012 , 141, 361-6	6.6	42
7	Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. <i>Digestive and Liver Disease</i> , 2012 , 44, 674-80	3.3	15

6	Treatment of chronic hepatitis D. <i>Journal of Viral Hepatitis</i> , 2007 , 14 Suppl 1, 58-63	3.4	30
5	Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2007 , 3, 22	3.2	62
4	Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?. <i>Blood</i> , 2006 , 107, 3409-10	2.2	3
3	Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. <i>Haematologica</i> , 2006 , 91, ECR26	6.6	10
2	Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. <i>Gastroenterology</i> , 2004 , 126, 1740-9	13.3	228
1	Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 3081-6	11.5	179